Stock has not been able to generate better return on equity than bank FD
Stock doesn't offer attractive dividend returns
Good time to consider, as stock is not in overbought zone
Stock not in ASM/GSM lists and not a lot of promoter holding is pledged
Chandra Bhagat Pharma Ltd is an India-based medicine company. The Company is engaged in the business of marketing pharmaceutical formulation and products in domestic and international markets through its distribution network and sales force under its own brand. It provides a range of products portfolio of a pharmaceutical formulation including injections (ampoules, vials, prefilled syringe, lyophilized vials), tablet, capsules and oral syrup. The Company’s products include for the domestic market mufost, mufost, herzovir, herzovir, clauvmentin, falsun, azap, azocin, chinofen, polodyl, casfungen, cbtaz, nuperazone, nuperazone forte, nuperazone plus, nuperazone 3g, cefzidime tz, cefzidime, cezoneplus, cezone tz, myocholine, klarinton, samcy, dobier s, maxiparine, antacer, cbfos, thionine, thromboparin, meplife combipack, merospect and norepirin.
Customise key metrics, see detailed forecasts, download stock data and more
In last 6 months, promoter holding in the company has decreased by 1.02%
Pledged promoter holdings is insignificant